Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Neoadjuvant therapy and PCR through chemotherapy prior to surgery

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3510

Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium

Prof Michail Ignatiadis talks to ecancer about neoadjuvant therapy and pathological complete response (PCR) at IMPAKT 2012 in Brussels, May 2012.


The study conducted looks at whether or not neoadjuvant therapy should be used in order to reach pathological complete response. Results have shown that this can occur after commonly used therapies.


Data shows that patients with HER2 amplified and triple negative tumours have excellent response when receiving chemotherapy before surgery. After treatment, biopsies can be used to determine tumour type and its sensitivity to chemotherapy for future record. The most important finding in the study was that the immune response module had a signficantly higher probability of complete pathological response.


Filming Supported by Amgen

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation